| 1.88 -0.04 (-2.08%) | 01-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.52 | 1-year : | 2.8 |
| Resists | First : | 2.16 | Second : | 2.4 |
| Pivot price | 2.02 |
|||
| Supports | First : | 1.77 | Second : | 1.48 |
| MAs | MA(5) : | 1.86  |
MA(20) : | 2.04 |
| MA(100) : | 2.45 |
MA(250) : | 2.98 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 16.1 |
D(3) : | 11.8 |
| RSI | RSI(14): 40.9 |
|||
| 52-week | High : | 5.78 | Low : | 1.77 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ALLO ] has closed above bottom band by 28.9%. Bollinger Bands are 3.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.93 - 1.94 | 1.94 - 1.95 |
| Low: | 1.83 - 1.85 | 1.85 - 1.86 |
| Close: | 1.86 - 1.88 | 1.88 - 1.9 |
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Thu, 26 Dec 2024
Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Mon, 16 Dec 2024
Allogene Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Thu, 12 Dec 2024
Allogene Therapeutics Mourns Loss of Founding Board Member David Bonderman, Pioneer in CAR T-cell Innovation - StockTitan
Mon, 02 Dec 2024
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock? - Yahoo Finance
Mon, 25 Nov 2024
Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 210 (M) |
| Held by Insiders | 1.5187e+008 (%) |
| Held by Institutions | 17.4 (%) |
| Shares Short | 35,050 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.5497e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -625 % |
| Return on Assets (ttm) | 246.4 % |
| Return on Equity (ttm) | -25.9 % |
| Qtrly Rev. Growth | 43000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -64.47 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -217 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 0.71 |
| Dividend | 0 |
| Forward Dividend | 3.237e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|